The Patent Finder

Accutar Biotechnology Inc.

Also on record
Records under this name other than the patents Accutar Biotechnology Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.

Back to Accutar Biotechnology Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,312,959Antisense oligonucleotides and their use for treating Pendred syndrome
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 12,168,058Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 12,195,459Glutarimide-Containing Pan-Kras-Mutant Degrader Compounds and Uses Thereof
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 12,110,291Glutarimide-Containing Pan-Kras-Mutant Degrader Compounds and Uses Thereof
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,420,956Novel Ureas Having Androgen Receptor Degradation Activity and Uses Thereof
Lapsed on the fee record
Ended Aug 23, 2026 · High confidence
Lapsed on the fee recordEnded Aug 23, 2026High confidence
US 11,312,702Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
Lapsed on the fee record
Ended Apr 26, 2026 · USPTO record
Lapsed on the fee recordEnded Apr 26, 2026USPTO record
US 9,944,632Compounds having estrogen receptor alpha degradation activity and uses thereof
Lapsed on the fee record
Ended Apr 17, 2026 · USPTO record
Lapsed on the fee recordEnded Apr 17, 2026USPTO record
US 11,220,490Novel Ureas Having Androgen Receptor Degradation Activity and Uses Thereof
Lapsed on the fee record
Ended Jan 11, 2026 · High confidence
Lapsed on the fee recordEnded Jan 11, 2026High confidence
US 11,117,885Compounds having estrogen receptor alpha degradation activity and uses thereof
Lapsed on the fee record
Ended Sep 14, 2025 · USPTO record
Lapsed on the fee recordEnded Sep 14, 2025USPTO record
US 10,968,212Compounds having estrogen receptor alpha degradation activity and uses thereof
Lapsed on the fee record
Ended Apr 6, 2025 · USPTO record
Lapsed on the fee recordEnded Apr 6, 2025USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited